Clinical trials
Carcinoma, Renal Cell trials in Argentina
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Active, not recruiting | 8 |
| Terminated | 5 |
| Recruiting | 3 |
| Approved for marketing | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 8 |
| Pfizer | 8 |
| Novartis Pharmaceuticals | 7 |
| Merck Sharp & Dohme LLC | 6 |
| Bayer | 2 |
| Exelixis | 2 |
| GlaxoSmithKline | 2 |
| Hoffmann-La Roche | 2 |
| AVEO Pharmaceuticals, Inc. | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 42 |
| Kidney Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Carcinoma | 4 |
| Neoplasm Metastasis | 4 |
| Neoplasms | 3 |
| Disease Progression | 2 |
| Melanoma | 2 |
| Adenoma, Islet Cell | 1 |
| Breast Neoplasms | 1 |
Trials
Showing 51 to 42 of 42. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.